ABSTRACT
INTRODUCTION
Gout is a urate crystal deposition disease that, when uncontrolled, is characterized by recurrent attacks (gout flares) of acute inflammatory arthritis of the peripheral joints.
Continued urate crystal deposition due to uncontrolled disease can also lead to painful and disfiguring tophi, kidney stones, and uric acid nephropathy. Gout is the most common type of inflammatory arthritis in men and postmenopausal women, affecting 1-4% of the Western developed population [1, 2] . Gout is a chronic, progressively degenerative disease, and even when the patient is not experiencing flares or other signs and symptoms, the disease is ongoing and worsening. If not appropriately treated, gout can cause permanent joint destruction, bone erosion, and kidney damage [3, 4] .
Risk factors for gout include dietary contributors, alcohol consumption, use of thiazide diuretics, and metabolic-related diseases (e.g., obesity, arterial hypertension, diabetes, hypercholesterolemia, coronary artery disease, congestive heart failure, and renal failure), as well as a genetic component, and in women, menopause [5] . The hallmark precursor to gout is hyperuricemia (serum uric acid [sUA] levels of [6.8 mg/dL [[400 lmol/L], i.e., the precipitation concentration for urate crystals) [6] . Hyperuricemia leads to the deposition of monosodium urate crystals (MSU) in musculoskeletal structures including joints, in kidneys, and in other connective tissue [7] . While diet and overproduction of uric acid can contribute (10%), the predominant cause of hyperuricemia is inefficient uric acid excretion (90%) [8] . A proportion of individuals may have both an overproduction and an inefficient excretion of uric acid [9] .
In most patients, gout cannot be effectively treated by lifestyle changes alone. For long-term pharmacologic management of gout, the treatment guidelines from the European League against Rheumatism [4] , the British Society of Rheumatology [10] , and the American College of Rheumatology (ACR) [11] recommend treatments aimed at decreasing sUA for patients with recurrent acute attacks, tophi, or radiographic gout changes. Effective urate-lowering treatment (ULT) maintains uric acid below the critical level, prevents further MSU crystal formation, and over time dissolves away existing crystals [4] . The 2012 ACR Guidelines suggest xanthine oxidase inhibitor therapy with allopurinol or febuxostat as the first-line pharmacologic approach. In case first-line therapies do not succeed in reaching sUA targets or are contraindicated, uricosuric agents that increase renal excretion of uric acid (such as probenecid, sulfinpyrazone, benzbromarone, isobromindione) can be used [12] . Lesinurad increases urinary uric acid excretion and was recently approved in the US and EU to be used in combination with a xanthine oxidase inhibitor in patients unable to achieve target sUA on a xanthine oxidase inhibitor alone [13] [14] [15] .
Hyperuricemia and gout are associated with comorbidities such as cardiovascular disease, chronic kidney disease (CKD), and metabolic syndrome including its components diabetes and hypertension [5, [16] [17] [18] [19] [20] [21] [22] [23] [24] . Patients with frequent gout attacks have higher prevalence of comorbid diseases, (e.g., CKD, hypertension, dyslipidemia, ischemic heart disease (IHD), heart failure, and arthritis) than those with infrequent attacks [25] . In addition, previous research has identified that morbidities associated with gout are directly related to gout disease severity [26] . Treatment challenges arise when patients have comorbid conditions and are being treated with multiple medications; these challenges include drug-drug interactions with treatments for renal disease or hepatic impairment, as well as with statins for the treatment of hypercholesterolemia [27] [28] [29] . Studies show that many patients with gout do not achieve treatment goals with current therapies, and the majority continue to experience recurrent acute attacks, further joint damage, and other complications [30] . Understanding morbidity prevalence and incidence rates in patients with gout is important for benchmarking optimal approaches to gout management and selecting optimal treatments for individual patients.
Patients with gout commonly have multiple comorbidities, with subsequent comorbidities arising as a result of the disease; this should be taken into consideration both in clinical practice and when conducting clinical trials in these patients. In this study, we analyzed the prevalence and incidence rates of potential disease-or treatment-related renal and cardiovascular morbidities in patients with established gout from databases in four countries, with eligibility criteria aligned with recent gout clinical trial inclusion criteria [31, 32] to provide a more appropriate context or baseline for understanding clinical trial rates of morbidities. CLEAR 1 (NCT01510158) and CLEAR 2 (NCT01493531) were two placebo-controlled, phase 3 trials that investigated the efficacy and safety of lesinurad (a selective uric acid reabsorption inhibitor) in combination with allopurinol in gout patients having an inadequate response to standard-of-care allopurinol, and were used here to help define cohort exclusion criteria and standardize age/sex distributions for the database study. The current analysis comprises data from patients in Germany (DE), the United Kingdom (UK), the US, and France (FR).
METHODS

Data Sources
This study uses a retrospective data analysis of patients with gout using health-care data extracted from electronic medical record and administrative claims databases. [39, 40] . A more detailed description of these databases can be found in Table 1 .
Study Design and Patients
Study Design
A longitudinal cohort study design was used to evaluate (1) established prevalent comorbidity and (2) prospective incident comorbidity, in patients with prevalent established gout and eligibility criteria aligned with recent gout clinical trials.
Observation Periods
The overall study design is illustrated in Fig. 1 . For the US, the UK and DE, the cohort baseline To investigate morbidity potentially associated with current gout treatments, ULT-treated cohorts of patients treated with allopurinol, or with febuxostat, were also defined (Fig. 1) . The first ULT treatment episode initiated after the main index date constituted the cohort entry criterion and defined the treatment episode index date. A treatment episode pre-index year and extended pre-index look-back were defined from the treatment episode index date. Follow-up for this cohort continued while on this first defined ULT treatment, i.e., until a switch or an add-on occurred or treatment disruption for a duration longer than the ''admissible gap'' (50% of the previous script's duration), which terminated the first treatment episode, or otherwise until an event occurred, or until disenrollment, or the end of the study period. Dose change was not considered a treatment episode termination.
Patient Inclusion and Exclusion Criteria
Since we aimed to investigate morbidity in a gout trial-aligned prevalent established gout cohort, inclusion criteria for the prospective cohort analysis included having prevalent established gout on the main index date (as assessed during the 1-year main pre-index period), being aged C18 years on the main index date, being continuously enrolled in the database during the pre-index year, and having at least one observation in the database after the index date (Fig. 2) .
Established were excluded from the analysis of incidence post-index of these morbidities. The incidence of the acute conditions in the post-index period was evaluated independent of their occurrence in the pre-index period.
Data were analyzed using SAS software version 9 (SAS Institute, Cary, NC, USA).
Compliance with Ethics Guidelines
This article is based primarily on previously and routinely collected data in the databases used for the study, in compliance with the rules for each database. The UK part of this study was 
RESULTS
Baseline Characteristics
In total, 71,622 (DE), 44,775 (UK), 313,311 (US), and 29,645 (FR) patients were identified with prevalent established gout as defined during the main pre-index year. After applying trial-aligned inclusion and exclusion criteria, the gout trial-aligned prevalent established gout cohorts comprised a total of 35,118 (DE), 24,607 (UK), 121,591 (US), and 17,338 (FR) patients (Fig. 2) .
The characteristics of the gout trial-aligned prevalent established gout cohort at baseline, on the index date, are shown in Table 2 . Patients from DE, the UK, and FR were similar with regard to age and body mass index (BMI), while patients from the US generally were younger. BMI was unavailable for US patients, and only available for a minority of patients in the other countries. Patients from the UK had the highest mean number of days on ULT during the 1-year pre-index period.
Several studied groups of co-medications of interest with respect to the outcomes studied were found to be common in the pre-index year (Table 2 ) [41] . Approximately, 22-38% of patients across countries were treated with diuretics and angiotensin-converting enzyme inhibitors, respectively. Drugs considered to potentially be associated with sUA decrease were taken by a large majority, 63-82%, and almost all patients were taking some drug with potential nephrotoxic effects.
Prior to the index date, a recorded diagnosis of essential hypertension was most prevalent in patients from DE and least prevalent in patients from the UK ( Table 2) . Obesity was most prevalent in patients from the UK and diabetes was most prevalent in patients from DE.
Standardized Prevalence Rates of Morbid Events
Standardized prevalence rates of morbidity events potentially associated with gout or gout treatment are presented in Table 3 ; for corresponding crude rates, see Table S2 in the supplementary materials.
Among renal conditions, diagnosis of CKD/renal failure was most prevalent in the UK (10.9%) followed by DE (6.7%);
prevalence of abnormal sCr was also highest in the UK (30.6%). Hypertension was the most prevalent cardiovascular diagnosis in all four countries, followed by IHD and myocardial infarction. For FR, inpatient hospitalization data were unavailable for most patients so outcomes that often require hospitalization may be underestimated Table 4 ; for corresponding crude rates, see Table S3 in the supplementary materials.
Estimated standardized incidence rates of new/worsening renal impairment ranged from (Table 4) .
For laboratory-based renal impairment, the incidence rates of sCr elevations of C1.59 over the pre-index baseline in these data with likely underreporting were 0.49 (FR), 0.71 (US), and 0.84 (UK, DE) in the overall cohort, in the subgroups with available laboratory data.
DISCUSSION
Patients with gout frequently have multiple comorbidities, including hypertension, CKD, cardiovascular disease, obesity, diabetes, and hyperlipidemia, all of which have a significant adverse impact on public health [25, 42] . In some cases (e.g., CKD), the presence of the comorbidity contributes to the progression of hyperuricemia and/or gout [43] . Whether gout or hyperuricemia themselves contribute to the Table 4 continued For FR, inpatient hospitalization data were unavailable for most patients so outcomes that often require hospitalization may be underestimated pathogenesis of gout comorbidities is an area of intensifying investigation.
The results presented herein confirm that there is a notable degree of comorbidity burden among patients with gout. In agreement with other studies [26, 44] , hypertension was the most prevalent cardiovascular diagnosis in gout patients, but there was also a high percentage of patients from each country with hyperlipidemia and/or diabetes. The clinical characteristics of the patients in this study were similar to those described in another recent large US population-based study of 36,431 patients with chronic gout [42] treated with allopurinol, febuxostat, or colchicine in which more than half had hypertension and hyperlipidemia, 19-23% had diabetes, and 9-12% had cardiovascular disease. As gout is known to increase the risk of mortality from cardiovascular disease and coronary heart disease [18] , and higher cardiovascular risk is associated with the severity of gout [45] , it is important to correctly identify and manage cardiovascular risk factors in patients with gout, and also to identify and optimally manage gout in patients at risk of cardiovascular disease. The findings from this study also demonstrate that patients with gout are subsequently diagnosed with other morbidity events.
Conclusions regarding differences between the two ULT treatment cohorts are difficult to draw due to the relatively low numbers of patients in the febuxostat cohort. A previous study reported that CKD was twice as common in febuxostat initiators compared with allopurinol or colchicine initiators [42] and that febuxostat initiators had more comorbid conditions, greater use of medications and health care resources compared with the other groups. This may be due to the fact that febuxostat is generally used as the second-line treatment after allopurinol and therefore patients are more likely to have more severe disease and/or comorbidities than those receiving first-line treatment. In our study, we noted numerically higher standardized CKD/ renal prevalence in the febuxostat than in the allopurinol cohort as the only consistent difference across countries for prevalence rates, while there was no consistent difference between the treatments for incidence of new/worsening renal impairment.
The associations between gout and occurrence of several comorbidities are well established [21] . For example, the association between gout and the components of metabolic syndrome can be explained, in part, through effects on urate production, renal angiotensin secretion, and renal urate excretion [46, 47] . Gout is also a known risk factor for cardiovascular diseases such as cerebrovascular disease, congestive heart failure, and myocardial infarction [48] [49] [50] [51] , collectively leading to an increased risk for all-cause and cardiovascular mortality in patients with gout [52] . A recent study of a large UK primary care database of patients with gout and matched controls found that risks for incident comorbidity were higher not only for cardiovascular, metabolic/endocrine, and musculoskeletal diseases, but also for genitourinary disease, liver diseases, hemiplegia, depression, anemia, and psoriasis [21] .
In our study, we saw relatively high This could be related to true differences in the populations, differences in disease course or treatment intensity between countries, and also to methodological and other differences in the databases analyzed. Since we mainly relied on the diagnosis codes and laboratory-specific data to select patients with gout and identify their comorbidities, potential misclassification bias is as always a caveat and may be different across the databases. In addition, the prevalence rates were assessed in a ''gout trial-aligned'' cohort of patients with prevalent established gout, meaning that subjects with some specific comorbidities of interest (cardiovascular diseases, liver conditions, severe CKD) documented 1 year prior to the main index date had been excluded from the analysis, which likely resulted in somewhat lower prevalence rates and, to a more limited extent, decreased incidence rates of some morbidity conditions. Several country-specific limitations to the study due to the nature of the individual databases used should also be discussed. In DE, the percentage of physicians represented (2.4%)
was not a random sample and was small. As a consequence, the patients sampled might not 
CONCLUSIONS
In summary, it is difficult to quantify an ''exact'' burden based on these data; nevertheless, this study fills an important current gap by providing a range of potentially relevant estimates of prevalence and incidence of these conditions, obtained using as consistent methodology as possible across databases, in a large real-world setting reflective of today's patient populations in these four countries. As a whole, our findings confirm that there is a notable degree of renal and cardiovascular comorbidity burden among patients with gout. Additionally, the results demonstrate that patients with gout, followed over time, continue to be frequently diagnosed with new significant morbidity events. Compliance with Ethics Guidelines. This article is based primarily on previously and routinely collected data in the databases used for the study, in compliance with the rules for each database. The UK part of this study was 
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